Fernanda Lauermann

Pelotas, Rio Grande do Sul 96020-260

0 studies enrolling now · 1 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer

Studies at this site

• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed